1. Home
  2. SKWD vs NRIX Comparison

SKWD vs NRIX Comparison

Compare SKWD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skyward Specialty Insurance Group Inc.

SKWD

Skyward Specialty Insurance Group Inc.

HOLD

Current Price

$44.35

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.16

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKWD
NRIX
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
SKWD
NRIX
Price
$44.35
$16.16
Analyst Decision
Buy
Strong Buy
Analyst Count
11
13
Target Price
$65.60
$29.46
AVG Volume (30 Days)
529.5K
1.3M
Earning Date
02-23-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
3.25
N/A
EPS
3.37
N/A
Revenue
$1,335,358,000.00
$83,980,000.00
Revenue This Year
$24.24
N/A
Revenue Next Year
$30.51
$20.16
P/E Ratio
$13.11
N/A
Revenue Growth
22.27
53.95
52 Week Low
$43.35
$8.18
52 Week High
$65.05
$22.50

Technical Indicators

Market Signals
Indicator
SKWD
NRIX
Relative Strength Index (RSI) 39.13 37.81
Support Level $44.34 $16.15
Resistance Level $45.81 $17.50
Average True Range (ATR) 1.34 1.10
MACD -0.03 -0.34
Stochastic Oscillator 29.88 2.21

Price Performance

Historical Comparison
SKWD
NRIX

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: